FOXO4-DRI research peptide — wholesale supply

For research use only · Not for human consumption · Not for veterinary use. This product is supplied for in-vitro research, analytical method development, and laboratory reference standard use only. Not approved for human or veterinary administration. Buyer is responsible for end-use classification in the destination jurisdiction.

Overview

FOXO4-DRI is a synthetic 46-amino-acid D-retro-inverso peptide research compound, derived from the FOXO4 transcription factor nuclear localisation signal. The D-retro-inverso form (D-amino acids in the reverse sequence) confers resistance to proteolytic degradation, which is the defining characteristic of the research compound. FOXO4-DRI is studied in cell-based research on FOXO4-p53 interaction, on senescent cell biology, and on the disruption of the FOXO4-p53 nuclear interaction in defined cell-based systems. SPK Pharma India supplies FOXO4-DRI as a research-grade lyophilized peptide, intended for in-vitro cell-based assays, senolytic pathway research, and analytical method development. The compound is supplied for research and analytical applications only, and is a niche research SKU with limited B2B supply globally.

Specifications

Research context

FOXO4-DRI is studied in cell-based research on the FOXO4-p53 protein-protein interaction, which has been investigated in the academic literature as a target for disrupting the survival of senescent cells in defined cell-based systems. The D-retro-inverso form confers resistance to proteolytic degradation, which is the defining research characteristic — the peptide is stable in cell culture for extended periods relative to the L-amino acid parent, which is the basis for its use in long-duration cell-based assays.

In-vitro cell-based assays in defined senescent cell models, protein-protein interaction studies (immunoprecipitation, proximity ligation assays), and analytical method development for LC-MS quantification of the peptide are typical research applications. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The compound is supplied strictly for in-vitro research, analytical method development, and reference-standard work.

For researchers new to the compound, the standard analytical reference points are CAS 2460055-23-4, the 46-amino-acid D-retro-inverso backbone, the approximate molecular weight of 5,338 g/mol, the lyophilized powder form, and the documented purity threshold (≥99% HPLC). The full amino acid sequence is disclosed on the lot-matched COA and on the product specification sheet.

Packaging and supply

• 5 mg research vial — for method development, cell-based assays, and reference-standard qualification. Standard MOQ: 5 vials.
• 10 mg research vial — for ongoing research programmes with higher per-assay demand. Standard MOQ: 2 vials.
• Bulk pack — on application, for annual supply contracts and recurring orders.

Distributor pricing is available on application. Annual supply contracts with scheduled recurring dispatch are available for repeat buyers. Lead time for in-stock SKUs is typically 5 business days from purchase order confirmation; lead time for scheduled production is typically 4 to 6 weeks. Note that FOXO4-DRI is a niche research SKU with limited B2B supply globally; lead times may be longer than the standard catalogue SKUs.

Quality and documentation

Every lot of FOXO4-DRI ships with a lot-matched Certificate of Analysis documenting identity (mass spectrometry and amino acid analysis), purity (HPLC), appearance, lot number, and synthesis batch reference. A representative sample of every lot is independently verified by a third-party analytical laboratory before release. MSDS is supplied with every shipment. The COA template, the lot-traceability workflow, and the third-party verification scope are documented on the Quality page.

Storage and handling

• Store at -20°C in the original sealed container.
• Protect from light and moisture.
• Allow the sealed container to reach room temperature before opening, to avoid condensation.
• Reconstitute in sterile, low-endotoxin research-grade water or in a mild buffer at the working concentration required by the assay.
• Do not refreeze once reconstituted; aliquot and store at working concentration.
• The D-retro-inverso form is resistant to proteolysis but should still be handled with standard peptide-handling care; avoid vigorous vortexing.

Shipping

FOXO4-DRI is shipped lyophilized in sealed vials within temperature-validated packaging. International lanes are routed through dedicated life-science logistics partners with cold-chain handling. Standard dispatch is within 5 business days of purchase order confirmation; lead time for niche SKUs may be longer. SPK Pharma India ships to the United States, the European Union, the United Kingdom, Canada, MENA, APAC, and LATAM. Full export documentation, including commercial invoice, packing list, certificate of origin, COA, and MSDS, is included with every shipment. Destination-specific documentation is supported on request.

Compliance

This product is supplied for research use only. It is not a drug, not a finished dosage form, and not approved for human or veterinary administration. SPK Pharma India does not make therapeutic, clinical, diagnostic, or dosing claims for this product. The buyer is responsible for end-use classification in the destination jurisdiction and for ensuring that downstream handling is consistent with research-use-only protocols.

Lead form CTA

To request a wholesale quote for FOXO4-DRI, contact the trade desk with the subject line "FOXO4-DRI wholesale quote" and your company details, expected volume, and destination country. Distributor pricing is available on application. The desk responds within one business day.

Related compounds

• Epitalon 10 mg — tetrapeptide bioregulator research peptide
• MOTS-C 20 mg — mitochondrial-derived research peptide
• NAD+ — research-grade bulk reference standard
• CJC-1295 without DAC (Modified GRF 1-29) — 29-amino-acid GHRH analogue research peptide
• FOXO4-DRI — 46-amino-acid D-retro-inverso research peptide